Skip to content
  • Tuesday, 30 June 2026
  • 8:18 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Bristol Myers Squibb Bets on Milvexian and Cobenfy to Drive Growth into the 2030s Amidst Patent Expiries
Pharmaceutical R&D

Bristol Myers Squibb Bets on Milvexian and Cobenfy to Drive Growth into the 2030s Amidst Patent Expiries

Teuku Ryan May 2, 2026 0

Bristol Myers Squibb (BMS) is strategically positioning itself for sustained growth through the 2030s, with upcoming pivotal Phase III readouts…

Read More
Breakthrough in MXene Synthesis Achieves Unprecedented Electrical Conductivity and Surface Precision Through Novel Molten Salt TechniqueAI Lab Result Interpretation Gains Traction with Patients, but Raises Accuracy and Validation Concerns for Clinical LaboratoriesSingaporean Scientists Unveil Revolutionary Spinach-Derived Photosynthetic Treatment for Chronic Dry Eye DiseaseRethinking Evidence Generation for Ultra-Rare Diseases
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveHigh-Dimensional Topological Structures Discovered in Entangled Photons Offer New Framework for Quantum Information StabilityWater-in-Diesel Emulsion Technology Offers Significant Emissions Reduction Potential Without Engine Modification
Glioblastoma Research Reveals Skull Erosion and Immune System Reprogramming Reshaping Treatment StrategiesPioneering Sequencing by Synthesis: David Klenerman Reflects on a Decade of Innovation and the Future of BiotechDiabetes to MASH: the specimens behind GLP-1’s widening rosterSeven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply Chain
YOU MAY HAVE MISSED
Stem Cell & Regenerative Medicine
Glioblastoma Research Reveals Skull Erosion and Immune System Reprogramming Reshaping Treatment Strategies
Dwi Wanna Jun 30, 2026
Biotech & Genetic Research
Pioneering Sequencing by Synthesis: David Klenerman Reflects on a Decade of Innovation and the Future of Biotech
Jia Lissa Jun 30, 2026
Laboratory Automation & Robotics
Diabetes to MASH: the specimens behind GLP-1’s widening roster
Lana Keisha Jun 30, 2026
Pharmaceutical R&D
Seven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply Chain
Teuku Ryan Jun 30, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ